Venous thromboembolism (VTE) is a life threatening disease, which is very common in adult patients with diffuse glioma. However, due to the possibility of intracerebral hemorrhage, there has been controversy about the prevention of thrombosis. At present, there are effective VTE prediction models for other cancer types, but there is no model for glioma. Recently, in a research report published on the international journal Blood entitled "Determining venous thromboembolism risk in patients with adult type diffuse glioma", scientists from Northwestern University and other institutions in the United States developed a new tool to help clinicians predict the risk of venous thromboembolism in patients with adult diffuse glioma.
Venous thromboembolism, a blood clot in the vein, usually endangers the life of patients with adult diffuse glioma, which is the most common malignant tumor in the brain. In order to develop a risk prediction tool, the researchers studied 483 newly diagnosed patients with adult diffuse glioma and analyzed their arterial blood, tumor tissue and other data. The results showed that there were seven factors that could help predict the increased risk of VTE in these patients, namely previous history of VTE, hypertension, asthma, increased white blood cell count, higher glioma grade, increased patient age, and increased BMI.
On the contrary, researchers have found that mutations in IDH1 or IDH2 genes, hypothyroidism, and inactivation of MGMT genes may all help predict a decrease in VTE risk in the body; Researchers have combined these 10 variables to develop a new web-based VTE prediction tool. Craig M Horbinski, a medical doctor, said that now for the first time, we have made evidence-based prediction specifically for venous thromboembolism in patients with glioma. This tool is a web-based calculator. You can input basic information about patients and tumors, and then you can get the risk percentage of patients for 1, 3, 6, and 12 months. With this information, clinical doctors can measure the risk of thrombosis in the patient's body and other risks associated with preemptive use of anticoagulants, which can sometimes cause cerebral hemorrhage.
Researchers have stated that when we informally investigate how clinical doctors assess the risk of these blood clots, we have obtained various answers, which may entirely depend on their level of enthusiasm for antithrombotic prevention. Clinical doctors can first inject heparin into patients, but often do not knowwhether a particular patient actually has a risk of thrombosis. Additionally, heparin administration is also very painful and may increase the risk of cerebral hemorrhage, Prior to this, there had never been strict evidence to guide decision-making. Currently, researchers are planning further trials on high-risk patients to validate this new tool and provide better guidance on which patients can benefit the most from preventive anticoagulants.
In summary, this study expands scientists' understanding of the VTE blueprint in adult diffuse gliomas and can provide evidence-based guidance strategies for clinicians to reduce the risk of VTE in glioma patients.
